New drug combo shows promise against advanced cervical cancer in early trial
NCT ID NCT06511726
First seen Jun 05, 2026 · Last updated Jun 15, 2026 · Updated 3 times
Summary
This study tests whether adding a new immunotherapy drug (cadonilimab) to chemotherapy before standard radiation can shrink tumors better in people with locally advanced cervical cancer. The trial involves 29 participants and aims to see how many respond to the treatment. Researchers will also monitor side effects and how long the benefits last.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen Memorial hosipital
Guangzhou, Guangdong, 510000, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.